Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-54499
Brüllmann, S; Dichtl, W; Paoli, U; Haegeli, L; Schmied, C; Steffel, J; Brunckhorst, C; Hintringer, F; Seifert, Burkhardt; Duru, F; Wolber, T (2012). Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients Aged ≥75 years versus those <75 years. American Journal of Cardiology, 109(5):712-717.
PDF - Registered users only
Implantable cardioverter-defibrillator (ICD) therapy decreases arrhythmic and all-cause mortality in patients at high risk of sudden death. However, its clinical benefit in elderly patients is uncertain. The aim of this study was to assess the long-term efficacy of ICD treatment in elderly patients and to identify markers of successful ICD therapy and risk factors of mortality. We performed multivariate analysis of a prospective long-term database from 2 tertiary care centers including 936 consecutive patients with an ICD. Predictors of ICD therapy and risk factors for mortality were assessed in patients ≥75 years old at ICD implantation compared to younger patients. Mean follow-up time was 43 ±40 months. Rates of ICD therapy were similar in the 2 age groups. No significant predictors of ICD therapy could be identified in older patients. Median estimated survival was 132 months in patients <75 years and 81 months in those ≥75 years old (p = 0.006). Decreased ejection fraction (hazard ratio 1.62 per 10% decrease, p = 0.03) and impaired renal function (hazard ratio 1.57 per 10 ml/kg/m(2) decrease in estimated glomerular filtration rate, p = 0.02) were independent risk factors of mortality in patients ≥75 years old. However, mortality of older patients was similar to that of the age-matched general population irrespective of delivery of ICD therapy. In conclusion, ICD therapy is effective for treatment of life-threatening arrhythmias in all age groups. However, prevention of sudden cardiac death may have limited impact on overall mortality in older patients. Despite a similar rate of appropriate ICD therapies, risk of death is increased 1.6-fold in ICD recipients ≥75 years old compared to younger patients. Patients with decreased ejection fraction and impaired renal function are at highest risk.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Institute of Social and Preventive Medicine|
|DDC:||610 Medicine & health|
|Deposited On:||26 Jan 2012 11:17|
|Last Modified:||09 Dec 2013 10:55|
|Citations:||Web of Science®. Times cited: 1|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page